Abstract
A total of 28 patients were treated with mitoxantrone, vinorelbine and prednisone every 3 weeks. In all, 11 patients (46%) had a significant prostate-specific antigen decline for a median duration of 11.4 months. Eight patients (33%) achieved a partial response on pain, while seven (29%) obtained a stabilisation of the symptom. Median duration of the response was 9.5 months. A confirmed partial response was obtained in three out of seven patients who had bidimensionally measurable disease. Toxicity was manageable. Our study provides further support to the concept of combined antimicrotubule therapy for metastatic harmonoresistant prostate cancer, promoting the exploration of new regimens containing antimicrotubule agents in addition to mitoxantrone–prednisone.
Similar content being viewed by others
References
Parker SL, Tong T, Bolden S, Wingo PA . Cancer statistics. CA Cancer J Clin 1997; 47: 5–27.
Goktas S, Crawford ED . Optimal hormonal therapy for advanced prostatic carcinoma. Semin Oncol 1999; 26: 162–173.
Oh WK . Chemotherapy for patients with advanced prostate carcinoma. Cancer 2000; 88: 3015–3021.
Culine S, Droz J-P . Chemotherapy in advanced androgen-independent prostate cancer 1990–1999: A decade of progress? Ann Oncol 2000; 11: 1523–1530.
Eisenberger MA . Chemotherapy for prostate carcinoma. NCI Monogr 1988; 7: 151–163.
Yagoda A, Petrylak D . Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993; 71: 1098–1099.
Dawson NA . Response criteria in prostatic carcinoma. Semin Oncol 1999; 26: 174–184.
Bubley GJ et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen working group. J Clin Oncol 1999; 17: 3461–3467.
Tannock IF et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points. J Clin Oncol 1996; 14: 1756–1764.
Kantoff PW et al. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: results of the Cancer and Leukemia Group B 9182 study. J Clin Oncol 1999; 17: 2506–2513.
Isaacs JT . The biology of hormone-refractory prostate cancer: why does it develop? Urol Clin North Am 1999; 26: 263–273.
Depierre A et al. A phase II study of navelbine (vinorelbine) in the treatment of non-small-cell lung cancer. Am J Clin Oncol 1991; 14: 115–119.
Le Chevalier T et al. Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancers: results of a European multicenter trial including 612 patients. J Clin Oncol 1994; 12: 360–367.
Marty M et al. A review of antitumour activity of vinorelbine in breast cancer. Drugs 1992; 44: 29–35.
Fields-Jones S et al. Improvements in clinical benefit with vinorelbine in the treatment of hormone-refractory prostate cancer: a phase II trial. Ann Oncol 1999; 10: 1307–1310.
Morant R et al. Vinorelbine in androgen-independent metastatic prostate carcinoma — a phase II study. Eur J Cancer 2002; 38: 1626–1632.
WHO Handbook for reporting results of cancer treatment. WHO Offset Publication No. 48. Geneva, Switzerland, World Health Organization, 1979.
Oudard S et al. Phase II study of vinorelbine in patients with androgen-independent prostate cancer. Ann Oncol 2001; 12: 847–852.
Houde RW . Methods for measuring clinical pain in humans. Acta Anaesthesiol Scand 1982; 74:(Suppl): 25–29.
Kelly WK et al. Prostate specific antigen as a measure of disease outcome in metastatic hormono-refractory prostate cancer. J Clin Oncol 1993; 11: 607–615.
Sweeney CJ et al. A phase II Hoosier Oncology Group study of vinorelbine and estramustine phosphate in hormone-refractory prostate cancer. Ann Oncol 2002; 13: 435–440.
Colleoni M et al. Phase II study of estramustine, oral etoposide, and vinorelbine in hormone-refractory prostate cancer. Am J Clin Oncol 1997; 20: 383–386.
Smith MR et al. Vinorelbine and estramustine in androgen-independent metastatic prostate cancer. A phase II study. Cancer 2000; 89: 1824–1828.
Hudes GR et al. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer. J Clin Oncol 1997; 15: 3156–3163.
Smith DC et al. Phase II trial of oral estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer. J Clin Oncol 1999; 17: 1664–1671.
Savarese DM et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J Clin Oncol 2001; 19: 2509–2516.
Oudard S et al. Preliminary results of a phase II randomized trial of docetaxel, estramustine and prednisone—two schedules versus mitoxantrone and prednisone in patients with hormone refractory prostate cancer. Proc Am Soc Clin Oncol 2002; 21: 177a (abstract 706).
Sinibaldi VJ et al. Phase II evaluation of docetaxel plus one-day oral estramustine phosphate in the treatment of patients with androgen independent prostate carcinoma. Cancer 2002; 94: 1457–1465.
Acknowledgements
This work was supported by the ISS (Istituto Superiore di Sanità) and AIRC (Associazione Italiana per la Ricerca sul Cancro) grants.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bernardi, D., Talamini, R., Zanetti, M. et al. Mitoxantrone, vinorelbine and prednisone (MVD) in the treatment of metastatic hormonoresistant prostate cancer — a phase II trial. Prostate Cancer Prostatic Dis 7, 45–49 (2004). https://doi.org/10.1038/sj.pcan.4500685
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.pcan.4500685
- Springer Nature Limited